Drug Approval | September 09, 2021
Merck’s KEYTRUDA receives China approval for Esophageal cancer
The medicine is now approved for eight indications across five different types of cancer in China.
The medicine is now approved for eight indications across five different types of cancer in China.
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
Plasmacluster technology significantly inactivates SARS-CoV-2 contained in adherent saliva in an environment with 60% humidity where the physiological protective function is maintained
As of FY21, it is the largest independent medical device company and the second-largest company overall, in the surgical consumables market in India with a 7.91 per cent share based on the value
Amptron’s R &D is based out of the US and this will enable Max to obtain US and other global certifications. Max will retain the right to market, sell and distribute the products in India.
Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence
The focus is on wellness and personal care products
According to WHO, over 1.5 million people died of TB in 2020
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
Subscribe To Our Newsletter & Stay Updated
